Comparison of Homologous Recombination Repair Gene Next-Generation Sequencing Analysis in Patients With Metastatic Castration-Resistant Prostate Cancer Between Local and Central Laboratories in Korea

BACKGROUND: Following success of the phase III PROfound trial, the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib was approved by the US Food and Drug Administration in May 2020 for adult patients with deleterious homologous recombination repair (HRR) gene-mutated metastatic castration-resis...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yoonjung, Park, Inho, Kim, Boyeon, Choi, Yu Jeong, Oh, Seoung Chul, Lee, Kyung-A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Laboratory Medicine 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467836/
https://www.ncbi.nlm.nih.gov/pubmed/36045058
http://dx.doi.org/10.3343/alm.2023.43.1.64

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467836/
https://www.ncbi.nlm.nih.gov/pubmed/36045058
http://dx.doi.org/10.3343/alm.2023.43.1.64

Ejemplares similares